{"id":356028,"date":"2026-11-19T16:17:44","date_gmt":"2026-11-19T10:47:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=356028"},"modified":"2026-11-19T16:17:44","modified_gmt":"2026-11-19T10:47:44","slug":"anuh-pharma-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/","title":{"rendered":"Anuh Pharma Analyst Review 2027: Profit Up 47% on Flat Sales and a Near Debt-Free Book"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Anuh Pharma Stock Snapshot (19 Nov 2026)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b979.68<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b999.50 \/ \u20b967.00<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b9798 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 16.7 vs 51.5<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9185.24 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b911.21 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Anuh Pharma analyst review 2027<\/strong> finds no brokerage coverage as of November 2026. Q2 FY27 revenue was flat at \u20b9185.24 crore, down 0.3% from \u20b9185.88 crore, but net profit rose 47.3% to \u20b911.21 crore as margins improved. The stock traded at \u20b979.68 on 19 November 2026, about 17 times earnings against an industry level near 51, so any <strong>Anuh Pharma share price target 2027<\/strong> view depends on whether revenue growth returns.<\/p>\n<\/div>\n<p>The <strong>Anuh Pharma analyst review 2027<\/strong> covers a Mumbai-based maker of active pharmaceutical ingredients, the bulk drug substances that formulation companies turn into tablets and capsules. Readers searching for an <strong>Anuh Pharma share price target 2027<\/strong> will not find any named <strong>brokerage<\/strong> figure, so results and valuation guide this review.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/anuhphr\/anuh-pharma-ltd-share-price-today\">Anuh Pharma<\/a> traded at \u20b979.68 on 19 November 2026, about 20% below its 52-week high of \u20b999.50 and about 19% above its low of \u20b967. This Anuh Pharma analyst review 2027 explains how profit rose on flat sales and what shapes the <strong>Anuh Pharma stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=anuh-pharma-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#What_Analysts_Say_in_the_Anuh_Pharma_Analyst_Review_2027\" title=\"What Analysts Say in the Anuh Pharma Analyst Review 2027\">What Analysts Say in the Anuh Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Q2_FY27_Results_in_the_Anuh_Pharma_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Anuh Pharma Analyst Review 2027\">Q2 FY27 Results in the Anuh Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#How_Anuh_Pharma_Makes_Money\" title=\"How Anuh Pharma Makes Money\">How Anuh Pharma Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Growth_Triggers_in_the_Anuh_Pharma_Analyst_Review_2027\" title=\"Growth Triggers in the Anuh Pharma Analyst Review 2027\">Growth Triggers in the Anuh Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Key_Risks_in_the_Anuh_Pharma_Analyst_Review_2027\" title=\"Key Risks in the Anuh Pharma Analyst Review 2027\">Key Risks in the Anuh Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Anuh_Pharma_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Anuh Pharma Analyst Review 2027: Stock at a Glance\">Anuh Pharma Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#What_to_Watch_After_the_Anuh_Pharma_Analyst_Review_2027\" title=\"What to Watch After the Anuh Pharma Analyst Review 2027\">What to Watch After the Anuh Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Final_Word_on_the_Anuh_Pharma_Analyst_Review_2027\" title=\"Final Word on the Anuh Pharma Analyst Review 2027\">Final Word on the Anuh Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#What_does_the_Anuh_Pharma_analyst_review_2027_show\" title=\"What does the Anuh Pharma analyst review 2027 show?\">What does the Anuh Pharma analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Is_there_an_Anuh_Pharma_share_price_target_2027_from_brokerages\" title=\"Is there an Anuh Pharma share price target 2027 from brokerages?\">Is there an Anuh Pharma share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#What_does_Anuh_Pharma_make\" title=\"What does Anuh Pharma make?\">What does Anuh Pharma make?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#How_steady_are_Anuh_Pharmas_recent_results\" title=\"How steady are Anuh Pharma&#8217;s recent results?\">How steady are Anuh Pharma&#8217;s recent results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#Is_Anuh_Pharma_stock_undervalued_based_on_the_Anuh_Pharma_analyst_review_2027\" title=\"Is Anuh Pharma stock undervalued based on the Anuh Pharma analyst review 2027?\">Is Anuh Pharma stock undervalued based on the Anuh Pharma analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#What_risks_does_the_Anuh_Pharma_analyst_review_2027_highlight\" title=\"What risks does the Anuh Pharma analyst review 2027 highlight?\">What risks does the Anuh Pharma analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/anuh-pharma-analyst-review\/#What_should_investors_track_after_the_Anuh_Pharma_analyst_review_2027\" title=\"What should investors track after the Anuh Pharma analyst review 2027?\">What should investors track after the Anuh Pharma analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Anuh_Pharma_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Anuh Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No named <strong>brokerage<\/strong> covers Anuh Pharma. Promoters hold about 71.8% and institutions almost nothing, so the free float is small and research interest is limited.<\/p>\n<p>Valuation against pharma peers is the clearest reference point. The stock trades at about one-third of the industry earnings multiple, and this Anuh Pharma analyst review 2027 looks at whether that gap is justified.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Anuh_Pharma_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Anuh Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>\u20b9185.24 crore<\/td>\n<td>\u20b9185.88 crore<\/td>\n<td>Down 0.3%<\/td>\n<\/tr>\n<tr>\n<td>Net profit<\/td>\n<td>\u20b911.21 crore<\/td>\n<td>\u20b97.61 crore<\/td>\n<td>Up 47.3%<\/td>\n<\/tr>\n<tr>\n<td>Net margin<\/td>\n<td>About 6.1%<\/td>\n<td>About 4.1%<\/td>\n<td>Up about 200 bps<\/td>\n<\/tr>\n<tr>\n<td>H1 FY27 revenue<\/td>\n<td>\u20b9379.05 crore<\/td>\n<td>Not compared<\/td>\n<td>Steady<\/td>\n<\/tr>\n<tr>\n<td>H1 FY27 net profit<\/td>\n<td>\u20b922.63 crore<\/td>\n<td>Not compared<\/td>\n<td>Steady<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Sales were flat, but <strong>net profit<\/strong> rose sharply because margins improved by about two percentage points. Lower raw material costs or a better product mix usually explain this kind of gain in an API business.<\/p>\n<p>The June quarter was similar, with revenue of \u20b9193.81 crore and profit of \u20b911.42 crore, so the first half shows a steady run rate of about \u20b911 crore a quarter. In this Anuh Pharma analyst review 2027, that steadiness is a positive, while flat revenue is the weak spot.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Anuh_Pharma_Makes_Money\"><\/span><strong>How Anuh Pharma Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Anuh makes bulk drugs at its plant in Maharashtra and sells them to formulation makers in India and abroad.<\/p>\n<ul>\n<li><strong>Macrolide antibiotics:<\/strong> erythromycin and related antibiotic ingredients.<\/li>\n<li><strong>Anti-tuberculosis drugs:<\/strong> ingredients used in TB treatment programmes.<\/li>\n<li><strong>Other APIs:<\/strong> a range of established molecules for domestic and export buyers.<\/li>\n<li><strong>Exports:<\/strong> sales to regulated and semi-regulated overseas markets.<\/li>\n<\/ul>\n<p>Trailing twelve-month net profit is about \u20b948 crore based on earnings per share of about \u20b94.77. That figure frames this Anuh Pharma analyst review 2027, since the company earns modest but consistent profit on revenue of roughly \u20b9750 crore a year.<\/p>\n<p>API makers of established molecules compete mainly on cost and reliability. Prices for older antibiotics can be volatile because Chinese producers supply many of the same intermediates, so margins move with input costs. Anuh&#8217;s long track record and regulatory approvals help it keep customers, but they give limited pricing power.<\/p>\n<p>The balance sheet is very strong, with <strong>debt to equity<\/strong> of about 0.05, and the company pays a regular dividend. Large pharma companies in the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index earn higher multiples because they sell branded or specialty products with better margins. Anuh&#8217;s lower valuation reflects its focus on older, competitive molecules and its single-digit net margins.<\/p>\n<p>Revenue growth is the missing piece. Sales have hovered between about \u20b9185 crore and \u20b9194 crore a quarter in FY27, so profit gains have come from margins rather than volume. Adding new molecules, winning more export approvals or gaining share in existing products would be needed for the next leg of growth, because margins in older antibiotics cannot keep expanding indefinitely.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Anuh_Pharma_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Anuh Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Margin gains:<\/strong> net margin up to about 6.1%.<\/li>\n<li><strong>Steady profit:<\/strong> about \u20b911 crore a quarter in H1 FY27.<\/li>\n<li><strong>Near debt-free:<\/strong> <strong>debt to equity<\/strong> of about 0.05.<\/li>\n<li><strong>Dividend:<\/strong> a yield of about 1.9% at the current price.<\/li>\n<li><strong>Low valuation:<\/strong> about 17 times earnings, central to any Anuh Pharma share price target 2027 view.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Anuh_Pharma_Analyst_Review_2027\"><\/span><strong>Key Risks in the Anuh Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Flat revenue:<\/strong> sales did not grow in <strong>Q2 FY27<\/strong>.<\/li>\n<li><strong>Price competition:<\/strong> Chinese suppliers in older antibiotics.<\/li>\n<li><strong>Raw material costs:<\/strong> input price swings affect margins.<\/li>\n<li><strong>Regulatory checks:<\/strong> plant inspections by overseas regulators.<\/li>\n<li><strong>Low free float:<\/strong> promoters own about 71.8%, a key point in the Anuh Pharma analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Anuh Pharma With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anuh_Pharma_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Anuh Pharma Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (19 Nov 2026)<\/td>\n<td>\u20b979.68<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b999.50 \/ \u20b967.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>About \u20b9798 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>About 16.7<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>About 51.5<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>About 2.2<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>About 13.3%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.05<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>About 1.9%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 17 is roughly one-third of the industry level of about 51, while return on equity is a reasonable 13%. In this Anuh Pharma analyst review 2027, the discount reflects flat sales and the competitive nature of older APIs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>71.82%<\/td>\n<td>71.80%<\/td>\n<td>Flat<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>0.00%<\/td>\n<td>0.11%<\/td>\n<td>Up 0.11 points<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>0.00%<\/td>\n<td>0.00%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>28.18%<\/td>\n<td>28.09%<\/td>\n<td>Down 0.09 points<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Bharti Shah holds 19.43% and Prafulla Shah 14.47%, and the <strong>promoter<\/strong> stake was steady. Foreign investors took a tiny stake, but institutional interest remains minimal, which the Anuh Pharma analyst review 2027 links to the small free float.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Anuh_Pharma_Analyst_Review_2027\"><\/span><strong>What to Watch After the Anuh Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Revenue growth:<\/strong> whether sales start rising again.<\/li>\n<li><strong>Margins:<\/strong> net margin holding near 6%.<\/li>\n<li><strong>New products:<\/strong> additions to the API portfolio.<\/li>\n<li><strong>Export demand:<\/strong> orders from overseas buyers.<\/li>\n<li><strong>Coverage:<\/strong> any research that sets an Anuh Pharma share price target 2027.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Anuh_Pharma_Analyst_Review_2027\"><\/span><strong>Final Word on the Anuh Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Anuh Pharma analyst review 2027<\/strong> shows a steady, nearly debt-free API maker with rising profit and a valuation far below pharma peers. Flat revenue and price competition in older molecules hold it back.<\/p>\n<p>The <strong>Anuh Pharma stock outlook 2027<\/strong> depends on revenue growth and margins. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Anuh_Pharma_analyst_review_2027_show\"><\/span><strong>What does the Anuh Pharma analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows higher profit on flat sales. Q2 FY27 revenue was \u20b9185.24 crore, down 0.3%, while net profit rose 47.3% to \u20b911.21 crore. Net margin improved to about 6.1% from about 4.1%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Anuh_Pharma_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Anuh Pharma share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No named brokerage target exists as of November 2026. The stock traded at \u20b979.68 on 19 November 2026, about 20% below its 52-week high of \u20b999.50. Valuation and results are the main reference points.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Anuh_Pharma_make\"><\/span><strong>What does Anuh Pharma make?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Anuh Pharma makes active pharmaceutical ingredients, including macrolide antibiotics such as erythromycin and anti-tuberculosis drugs. It sells to formulation makers in India and abroad. The company is based in Mumbai.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_steady_are_Anuh_Pharmas_recent_results\"><\/span><strong>How steady are Anuh Pharma&#8217;s recent results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Q1 FY27 revenue was \u20b9193.81 crore with profit of \u20b911.42 crore, and Q2 revenue was \u20b9185.24 crore with profit of \u20b911.21 crore. First-half profit was \u20b922.63 crore. The run rate is steady at about \u20b911 crore a quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Anuh_Pharma_stock_undervalued_based_on_the_Anuh_Pharma_analyst_review_2027\"><\/span><strong>Is Anuh Pharma stock undervalued based on the Anuh Pharma analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock trades at about 16.7 times earnings, roughly one-third of the industry P\/E of about 51.5. Return on equity is about 13% and debt is minimal. The discount reflects flat sales and competition in older APIs.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Anuh_Pharma_analyst_review_2027_highlight\"><\/span><strong>What risks does the Anuh Pharma analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are flat revenue, price competition from Chinese suppliers and raw material cost swings. Overseas plant inspections are an ongoing risk. Promoters hold about 71.8%, limiting the free float.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Anuh_Pharma_analyst_review_2027\"><\/span><strong>What should investors track after the Anuh Pharma analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether revenue starts growing again and net margin holds near 6%. Watch for new products and export orders. Dividend decisions also matter given the strong balance sheet.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Anuh Pharma analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows higher profit on flat sales. Q2 FY27 revenue was \u20b9185.24 crore, down 0.3%, while net profit rose 47.3% to \u20b911.21 crore. Net margin improved to about 6.1% from about 4.1%.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Anuh Pharma share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No named brokerage target exists as of November 2026. The stock traded at \u20b979.68 on 19 November 2026, about 20% below its 52-week high of \u20b999.50. Valuation and results are the main reference points.\"}},{\"@type\":\"Question\",\"name\":\"What does Anuh Pharma make?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Anuh Pharma makes active pharmaceutical ingredients, including macrolide antibiotics such as erythromycin and anti-tuberculosis drugs. It sells to formulation makers in India and abroad. The company is based in Mumbai.\"}},{\"@type\":\"Question\",\"name\":\"How steady are Anuh Pharma's recent results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Q1 FY27 revenue was \u20b9193.81 crore with profit of \u20b911.42 crore, and Q2 revenue was \u20b9185.24 crore with profit of \u20b911.21 crore. First-half profit was \u20b922.63 crore. The run rate is steady at about \u20b911 crore a quarter.\"}},{\"@type\":\"Question\",\"name\":\"Is Anuh Pharma stock undervalued based on the Anuh Pharma analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock trades at about 16.7 times earnings, roughly one-third of the industry P\/E of about 51.5. Return on equity is about 13% and debt is minimal. The discount reflects flat sales and competition in older APIs.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Anuh Pharma analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are flat revenue, price competition from Chinese suppliers and raw material cost swings. Overseas plant inspections are an ongoing risk. Promoters hold about 71.8%, limiting the free float.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Anuh Pharma analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether revenue starts growing again and net margin holds near 6%. Watch for new products and export orders. Dividend decisions also matter given the strong balance sheet.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anuh Pharma kept Q2 FY27 revenue flat at \u20b9185.24 crore but grew profit 47% to \u20b911.21 crore on better margins. With no brokerage coverage, we review the API business, first-half trends, the low valuation against pharma peers, the debt-free balance sheet and the risks for 2027.<\/p>\n","protected":false},"author":34,"featured_media":356027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,5491,4341,26614],"class_list":["post-356028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-active-pharmaceutical-ingredients","tag-analyst-review","tag-anuh-pharma"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["356027"],"rank_math_title":["Anuh Pharma Share Price Target 2027: Stock Review"],"rank_math_description":["Anuh Pharma analyst review 2027: Q2 FY27 revenue flat at \u20b9185 crore, profit up 47% to \u20b911.2 crore, P\/E near 17 vs industry 51, near debt-free, API price risks."],"rank_math_focus_keyword":["Anuh Pharma analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/anuh-pharma-analyst-review-2027-profit-up-47-on-flat-sales-and-a-near-debt-free.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=356028"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356028\/revisions"}],"predecessor-version":[{"id":356029,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/356028\/revisions\/356029"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/356027"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=356028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=356028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=356028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}